ASCO 2026 marked a clear inflection point in oncology. Brooks Hill Partners breaks down the meeting's defining themes — from pan-KRAS inhibitors unlocking treatment in pancreatic cancer, to bispecific antibodies expanding immunotherapy's reach, and ADCs emerging as a cornerstone of next-generation combination strategies. Underlying it all: a growing imperative to translate scientific breakthroughs into globally equitable access.

Clinical trials, a massive hurdle in the biopharmaceutical world, are often the rate-limiting step in drug development. Not only are clinica